EUVIMEDEUVIMED entdecken
Open Access

IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

Mark P van Opijnen iD, C Mircea S Tesileanu iD, Linda Dirven iD, Pim B van der Meer, Maarten M J Wijnenga, Arnaud J P E Vincent, Marike L D Broekman, Hendrikus J Dubbink, Johan M Kros, Sjoerd G van Duinen, Marion Smits iD, Pim J French und 3 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Mark P van Opijnen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Glioma, Epilepsy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or + 7/−10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy in the 2 glioblastoma subtypes.

Methods

We analyzed epilepsy data of an existing cohort including IDHwt histologically lower-grade glioma WHO grade 2 and 3 with molecular glioblastoma-like profile (IDHwt hLGG) and IDHwt glioblastoma patients. Primary outcome was the incidence proportion of epilepsy during the disease course. Secondary outcomes included, among others, onset of epilepsy, number of seizure days, and antiepileptic drug (AED) polytherapy.

Results

Out of 254 patients, 78% (50/64) IDHwt hLGG and 68% (129/190) IDHwt glioblastoma patients developed epilepsy during the disease (P = .121). Epilepsy onset before histopathological diagnosis occurred more frequently in IDHwt hLGG compared to IDHwt glioblastoma patients (90% vs 60%, P < .001), with a significantly longer median time to diagnosis (3.5 vs 1.3 months, P < .001). Median total seizure days was also longer for IDHwt hLGG patients (7.0 vs 3.0, P = .005), and they received more often AED polytherapy (32% vs 17%, P = .028).

Conclusions

Although the incidence proportion of epilepsy during the entire disease course is similar, IDHwt hLGG patients show a significantly higher incidence of epilepsy before diagnosis and a significantly longer median time between first seizure and diagnosis compared to IDHwt glioblastoma patients, indicating a distinct clinical course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsGliomaEpilepsyHumansMutationSeizuresAnticonvulsantsIsocitrate Dehydrogenase

Stichwörter der Autor:innen

IDHwtepilepsyglioblastomagliomaseizure

Substanzen

AnticonvulsantsIsocitrate DehydrogenaseIDH1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Neurosurgery, Haaglanden Medical Center, The Hague, the Netherlands.
  • Department of Neurology, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
  • Department of Neurosurgery, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Pathology, the Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

ORCID-Profile: Mark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, Marion Smits

Zitieren

APA

van Opijnen, M. P., Tesileanu, C. M. S., Dirven, L., van der Meer, P. B., Wijnenga, M. M. J., Vincent, A. J. P. E., Broekman, M. L. D., Dubbink, H. J., Kros, J. M., van Duinen, S. G., Smits, M., French, P. J., van den Bent, M. J., Taphoorn, M. J. B., & Koekkoek, J. A. F. (2023). IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac197

Vancouver

van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent AJPE, et al. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac197

BibTeX
@article{vanOpijnen2023,
  author = {van Opijnen, Mark P and Tesileanu, C Mircea S and Dirven, Linda and van der Meer, Pim B and Wijnenga, Maarten M J and Vincent, Arnaud J P E and Broekman, Marike L D and Dubbink, Hendrikus J and Kros, Johan M and van Duinen, Sjoerd G and Smits, Marion and French, Pim J and van den Bent, Martin J and Taphoorn, Martin J B and Koekkoek, Johan A F},
  title = {IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac197}
}
Kostenlos starten →